Corona Vaccine News | Phase-1 trials results of Covaxin safe and effective | Phase-1 trials of covaxin revealed results; This vaccine made in the country is safe and effective » India News
Connect with us

India News

Corona Vaccine News | Phase-1 trials results of Covaxin safe and effective | Phase-1 trials of covaxin revealed results; This vaccine made in the country is safe and effective

Published

on

  • Hindi news
  • National
  • Corona Vaccine News | Phase 1 Trials Results Of Covaxin Safe And Effective

Fed up with Ads? Install Dainik Bhaskar app for news without ads

new Delhi4 hours ago

Swadeshi Corona Vaccine – There is good news from Bharat Biotech, a company making covaxin. Phase-1 trials of covaxin have resulted in the foreign journal Med-Archive (medRxiv). It claims that the vaccine is completely safe and effective. It has not caused any serious side-effects.

Covaxin is one of the three vaccines for which emergency approval has been sought from drug regulators. In November itself, phase-3 trials have been started on 25,800 people at 25 sites across the country.

Doses to 375 volunteers with a difference of 14 days

The Hyderabad-based company, Bharat Biotech, developed the vaccine in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV). Phase-1 clinical trial was conducted to test the safety and immunogenicity of the BBV152 (covaxin) vaccine. During this time 375 volunteers were placed in three groups. They were given different doses. Two doses were given with a difference of 14 days.

Mild side effects were seen, they also cured

According to the report published in the journal, most volunteers had mild side-effects. These were also resolved soon. There was a serious side-effect report, but it was found that it had nothing to do with vaccination. All three groups showed very good and strong immune response. The results of different doses also did not show much difference. At the same time, the properties of elimination of some strains of coronavirus appeared in all volunteers.

The vaccine can be stored between 2 and 8 ° C.

Reports say that this vaccine can be stored between 2 to 8 degrees Celsius. This is in accordance with the cold chain requirements of the National Immunization Program.

Both formulations were selected for Phase-2 immunogenicity trials. Phase-2 trials of covaxin are over. But its results have not been revealed yet.

Advertisement

bareilly